Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 30:13:171.
doi: 10.3389/fncel.2019.00171. eCollection 2019.

Mast Cells in Neurodegenerative Disease

Affiliations

Mast Cells in Neurodegenerative Disease

Michael K Jones et al. Front Cell Neurosci. .

Abstract

Neurodegenerative diseases affect millions of people worldwide, yet there are currently no effective treatments. Because risk of neurodegenerative disease substantially increases with age, greater life expectancy with a concomitant aging population means more individuals will be affected in the coming decades. Thus, there is an urgent need for understanding the mechanisms driving neurodegenerative diseases in order to develop improved treatment strategies. Inflammation in the nervous system, termed "neuroinflammation," has become increasingly recognized as being associated with neurodegenerative diseases. Early attention focused primarily on morphological changes in astrocytes and microglia; however, brain and CNS resident mast cells are now receiving attention as a result of being "first responders" to injury. Mast cells also exert profound effects on their microenvironment and neighboring cells including behavior and/or activation of astrocytes, microglia, and neurons, which, in turn, are implicated in neuroinflammation, neurogenesis and neurodegeneration. Mast cells also affect disruption/permeability of the blood brain barrier enabling toxin and immune cell entry exacerbating an inflammatory microenvironment. Here, we discuss the roles of mast cells in neuroinflammation and neurodegeneration with a focus on development and progression of four prominent neurodegenerative diseases: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Huntington's Disease.

Keywords: Alzheimer’s; Huntington’s; Parkinson’s; amyotrophic lateral sclerosis; mast cells; neurodegenerative disease; neuroinflammation.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Proposed mechanisms of mast cell involvement in neurodegenerative diseases. (A) In Alzheimer’s Disease, microglia (MG) phagocytosis of amyloid β (Aβ) fragments may trigger release of mediators causing mast cell (M) degranulation. Mast cell products may in turn promote microglia-mediated neurotoxicity. (B) In Parkinson’s Disease, misfolded α-synuclein (α-S) may trigger microglia-mediated death of dopaminergic neurons. Astrocytes (Astro), microglia and dying neurons may all promote mast cell recruitment and release of mediators that exacerbate neuronal death. (C) In amyotrophic lateral sclerosis, TNF-α and IL-6 elaborated by microglia may drive mast cell recruitment, activation, and degranulation. Release of mediators such as tryptase and IL-8 can reciprocally activate microglia, exacerbating blood-brain barrier (BBB) disruption and release of pro-inflammatory cytokines. (D) Similarly, in Huntington’s Disease a feed-forward interaction between microglia and mast cells may promote a pro-inflammatory and neurotoxic milieu.

References

    1. Banuelos-Cabrera I., Valle-Dorado M. G., Aldana B. I., Orozco-Suarez S. A., Rocha L. (2014). Role of histaminergic system in blood-brain barrier dysfunction associated with neurological disorders. Arch. Med. Res. 45 677–686. 10.1016/j.arcmed.2014.11.010 - DOI - PubMed
    1. Bianchetti A., Ranieri P., Margiotta A., Trabucchi M. (2006). Pharmacological treatment of Alzheimer’s disease. Aging Clin. Exp. Res. 18 158–162. - PubMed
    1. Borsini A., Zunszain P. A., Thuret S., Pariante C. M. (2015). The role of inflammatory cytokines as key modulators of neurogenesis. Trends Neurosci. 38 145–157. 10.1016/j.tins.2014.12.006 - DOI - PubMed
    1. Bouwens J. A., van Duijn E., Cobbaert C. M., Roos R. A. C., van der Mast R. C., Giltay E. J. (2017). Disease stage and plasma levels of cytokines in Huntington’s disease: a 2-year follow-up study. Mov. Disord. 32 1103–1104. 10.1002/mds.26950 - DOI - PubMed
    1. Brites D., Vaz A. R. (2014). Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front. Cell. Neurosci. 8:117. 10.3389/fncel.2014.00117 - DOI - PMC - PubMed

LinkOut - more resources